Literature DB >> 32207079

The Effect of Orexin Receptor Antagonism on Quinpirole-Induced Compulsive-Like Checking Behavior in Rats.

Mahdi Abounoori1, Mohammad Moein Maddah1, Esmaeil Akbari2,3, Gholamreza Houshmand4, Motahareh Rouhi Ardeshiri5,6.   

Abstract

The orexinergic system supposedly plays a role in stress circuits for arousing behaviors during anxiety, suggesting that it may play a role also in neural circuits mediating the compulsive behavior characteristic of obsessive-compulsive disorder (OCD). This study aims to investigate the roles of the orexinergic system in the development of OCD behaviors, using as preparation the induction of compulsive checking by chronic treatment with the D2/D3 agonist, quinpirole. Repeated injections of quinpirole (0.5 mg/kg, twice per week for a total of 10 injections) were used to induce compulsive checking. In separate groups of rats, OX1R (SB334867-A; 10 μg i.c.v) and OX2R (TCS-OX2-29; 10 μg i.c.v) receptor antagonists were co-administered together with quinpirole. Checking behavior in a large open field was measured after the first, fifth, and tenth injections of the drugs. SB334867-A attenuated checking behavior and the level of anxiety. TCS-OX2-29 administration ameliorated anxiety but did not block the development of compulsive checking. Orexin 1 receptors seem to play a more critical role than orexin 2 receptors in the induction of compulsive checking. Considering that the quinpirole sensitization model of OCD involves activation of dopamine systems and sensitization to quinpirole, it is suggested that neural interaction between orexigenic and dopamine systems may be important in the pathogenesis of OCD.

Entities:  

Keywords:  Obsessive-compulsive disorder; Orexin 1 receptor antagonist; Orexin 2 receptor antagonist; Quinpirole

Mesh:

Substances:

Year:  2020        PMID: 32207079     DOI: 10.1007/s12640-020-00196-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  3 in total

Review 1.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

Review 2.  An overview of the orexinergic system in different animal species.

Authors:  Idris A Azeez; Olumayowa O Igado; James O Olopade
Journal:  Metab Brain Dis       Date:  2021-07-05       Impact factor: 3.584

3.  Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder.

Authors:  Ria Gupta; Sidharth Mehan; Pranshul Sethi; Aradhana Prajapati; Abdulrahman Alshammari; Metab Alharbi; Haneen A Al-Mazroua; Acharan S Narula
Journal:  Brain Sci       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.